Coagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke-Reference-Cited by-同舟云学术

Coagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke

Published:2020-10-15 Issue:12 Volume:18 Page:3316-3324
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Rohmann Jessica L.¹²^ORCID,Huo Shufan¹³⁴,Sperber Pia S.¹⁴,Piper Sophie K.⁵⁶,Rosendaal Frits R.⁷,Heuschmann Peter U.⁸⁹,Endres Matthias¹³⁴¹⁰¹¹,Liman Thomas G.¹³⁴,Siegerink Bob¹⁷^ORCID

Affiliation:

1. Center for Stroke Research Berlin Charité – Universitätsmedizin Berlin Berlin Germany

2. Institute of Public Health Charité – Universitätsmedizin Berlin Berlin Germany

3. Klinik für Neurologie Charité – Universitätsmedizin Berlin Berlin Germany

4. Deutsches Zentrum für Herz‐Kreislauf‐Forschung DZHK Berlin Germany

5. Insitute for Biometry and Clinical Epidemiology Charité – Universitätsmedizin Berlin Berlin Germany

6. Berlin Institute of Health (BIH) Berlin Germany

7. Department of Clinical Epidemiology Leiden University Medical Center Leiden the Netherlands

8. Institute of Clinical Epidemiology and Biometry University of Würzburg Würzburg Germany

9. Clinical Trial Center Würzburg University Hospital Würzburg Würzburg Germany

10. German Center for Neurodegenerative Disease DZNE Charité – Universitätsmedizin Berlin Berlin Germany

11. Excellence Cluster Neurocure Charité – Universitätsmedizin Berlin Berlin Germany

Funder

Bundesministerium für Bildung und Forschung

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.15092

Reference35 articles.

1. Global stroke statistics

2. Risk and Cumulative Risk of Stroke Recurrence

3. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project.

4. Survival and recurrence following stroke. The Framingham study.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial;The Lancet Neurology;2024-01

2. Determination of the Potential Clinical Benefits of Small Molecule Factor XIa Inhibitors in Arterial Thrombosis;ACS Pharmacology & Translational Science;2023-06-30

3. Coagulation biomarkers for ischemic stroke;Research and Practice in Thrombosis and Haemostasis;2023-05

4. Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention;Journal of Stroke and Cerebrovascular Diseases;2022-10

5. The Influence of Plasma Prekallikrein Oligonucleotide Antisense Therapy on Coagulation and Fibrinolysis Assays: A Post-hoc Analysis;Thrombosis and Haemostasis;2022-08-17